Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models

HER2-ECD (human epidermal growth factor receptor 2 – extracellular domain) is a prominent therapeutic target validated for treating HER2-positive breast and gastric cancer, but HER2-specific therapeutic options for treating advanced gastric cancer remain limited. We have developed antibody-drug conj...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Wei-Ying, Hsu, Hung-Ju, Wu, Chun-Yi, Chen, Hong-Sen, Chou, Yu-Chi, Tsou, Yueh-Liang, Peng, Hung-Pin, Jian, Jhih-Wei, Yu, Chung-Ming, Chiu, Yi-Kai, Chen, Ing-Chien, Tung, Chao-Ping, Hsiao, Michael, Lin, Chia-Lung, Wang, Yong Alison, Wang, Andrew H-J., Yang, An-Suei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343809/
https://www.ncbi.nlm.nih.gov/pubmed/30365359
http://dx.doi.org/10.1080/19420862.2018.1541370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343809/
https://www.ncbi.nlm.nih.gov/pubmed/30365359
http://dx.doi.org/10.1080/19420862.2018.1541370

Ejemplares similares